| Line Item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS | |||||||
| Revenue | |||||||
| Cost of goods sold | |||||||
| Gross profit | |||||||
| Research and Development Expense | |||||||
| Selling, General and Administrative Expense | |||||||
| Other income | |||||||
| Operating loss for the period | |||||||
| Financial income | |||||||
| Financial expense | |||||||
| Loss for the period before taxes | |||||||
| Income taxes | |||||||
| Loss for the period | |||||||
| Loss attributable to equity holders | |||||||
| Items that may not be subsequently reclassified to profit or loss (net of tax) | |||||||
| Remeasurements of post-employment benefit obligations, net of tax | |||||||
| Items that may be subsequently reclassified to profit or loss (net of tax) | |||||||
| Currency translation differences | |||||||
| Total other comprehensive income | |||||||
| Total comprehensive loss for the year, net of tax | |||||||
| Loss attributable to equity holders | |||||||
| Basic loss per share (in EUR) | |||||||
| Diluted loss per share (in EUR) |